UBS Ups Biogen (BIIB) To Hold; Profile of 2 Analysts Covering AU Optronics (ADR) (AUO)

June 19, 2017 - By Migdalia James

Among 20 analysts covering Biogen Idec Inc. (NASDAQ:BIIB), 12 have Buy rating, 0 Sell and 8 Hold. Therefore 60% are positive. Biogen Idec Inc. has $450 highest and $268 lowest target. $343.53’s average target is 33.30% above currents $257.71 stock price. Biogen Idec Inc. had 41 analyst reports since July 23, 2015 according to SRatingsIntel. The rating was initiated by Atlantic Securities with “Overweight” on Friday, December 18. The stock of Biogen Inc (NASDAQ:BIIB) earned “Hold” rating by Jefferies on Tuesday, September 6. The stock of Biogen Inc (NASDAQ:BIIB) has “Outperform” rating given on Wednesday, June 29 by Bernstein. Robert W. Baird maintained the shares of BIIB in report on Friday, March 11 with “Neutral” rating. The stock of Biogen Inc (NASDAQ:BIIB) earned “Buy” rating by H.C. Wainwright on Tuesday, August 11. The company was downgraded on Thursday, March 16 by Morgan Stanley. The rating was maintained by RBC Capital Markets on Wednesday, October 7 with “Outperform”. The firm earned “Strong Buy” rating on Thursday, December 29 by Raymond James. RBC Capital Markets maintained the shares of BIIB in report on Monday, July 27 with “Outperform” rating. As per Wednesday, September 9, the company rating was initiated by Jefferies.

Among 8 analysts covering AU Optronics (NYSE:AUO), 2 have Buy rating, 2 Sell and 4 Hold. Therefore 25% are positive. AU Optronics had 10 analyst reports since July 30, 2015 according to SRatingsIntel. The stock has “Underperform” rating by Bernstein on Friday, March 3. Citigroup upgraded the stock to “Sell” rating in Thursday, April 7 report. The firm has “Neutral” rating by Nomura given on Friday, October 28. The company was upgraded on Monday, January 11 by JP Morgan. Bank of America upgraded the shares of AUO in report on Tuesday, July 19 to “Buy” rating. The firm has “” rating given on Thursday, July 30 by Fubon Bank. Credit Suisse upgraded AU Optronics Corp (ADR) (NYSE:AUO) on Wednesday, June 29 to “Outperform” rating. The stock has “Market Perform” rating by Bernstein on Friday, September 9. The firm has “Neutral” rating by KGI Securities given on Thursday, July 30. See AU Optronics Corp (ADR) (NYSE:AUO) latest ratings:

03/03/2017 Broker: Bernstein Old Rating: Mkt Perform New Rating: Underperform Downgrade

Investors sentiment decreased to 0.92 in 2016 Q4. Its down 0.08, from 1 in 2016Q3. It turned negative, as 90 investors sold Biogen Inc shares while 341 reduced holdings. 93 funds opened positions while 304 raised stakes. 183.23 million shares or 1.51% less from 186.04 million shares in 2016Q3 were reported. Ngam Advsr Limited Partnership holds 0.19% or 54,734 shares in its portfolio. Pinebridge Invs Ltd Partnership holds 0.39% in Biogen Inc (NASDAQ:BIIB) or 45,881 shares. North Star Investment Mngmt Corp reported 15 shares. Alexandria Lc accumulated 24 shares. Zurcher Kantonalbank (Zurich Cantonalbank) owns 81,056 shares or 0.24% of their US portfolio. Adell Harriman Carpenter owns 7,277 shares or 0% of their US portfolio. Old Mutual Global Investors (Uk) Limited has 432,572 shares. Oak Ridge Invests Limited Co holds 0.18% or 19,849 shares in its portfolio. Edgemoor Investment Advsr invested 0.03% in Biogen Inc (NASDAQ:BIIB). Roanoke Asset Mgmt Corp New York, New York-based fund reported 6,260 shares. State Bank Of Montreal Can holds 0.04% or 123,919 shares. Cantab Ptnrs Limited Liability Partnership has 2,299 shares for 0% of their portfolio. Los Angeles Cap Mngmt & Equity Research owns 21,854 shares or 0.05% of their US portfolio. Pictet Asset Management Limited has 0.65% invested in Biogen Inc (NASDAQ:BIIB) for 616,119 shares. Legacy Private holds 0.16% of its portfolio in Biogen Inc (NASDAQ:BIIB) for 4,235 shares.

Analysts await Biogen Inc (NASDAQ:BIIB) to report earnings on July, 20. They expect $4.83 earnings per share, down 7.29% or $0.38 from last year’s $5.21 per share. BIIB’s profit will be $1.01B for 13.34 P/E if the $4.83 EPS becomes a reality. After $5.20 actual earnings per share reported by Biogen Inc for the previous quarter, Wall Street now forecasts -7.12% negative EPS growth.

Since January 9, 2017, it had 2 insider purchases, and 5 insider sales for $4.84 million activity. $277,840 worth of Biogen Inc (NASDAQ:BIIB) shares were sold by Posner Brian S. Sandrock Alfred sold 973 shares worth $282,238. PANGIA ROBERT W sold $1.61 million worth of stock or 5,450 shares. The insider Vounatsos Michel bought 1,402 shares worth $380,433. $2.88M worth of stock was sold by Clancy Paul J on Monday, March 13.

Biogen Inc. is a biopharmaceutical company. The company has market cap of $53.96 billion. The Firm focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. It has a 16.16 P/E ratio. The Firm markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis , FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).

About 523,394 shares traded. Biogen Inc (NASDAQ:BIIB) has risen 4.94% since June 19, 2016 and is uptrending. It has underperformed by 11.76% the S&P500.